Jamila Louahed
Rixensart, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
IL-9 exerts biological function on antigen-experienced murine T cells and exacerbates colitis induced by adoptive transfer.
Journal: European journal of immunology
Published: October 01, 2019
Expression of tumor-associated antigens in breast cancer subtypes.
Journal: Breast (Edinburgh, Scotland)
Published: August 22, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 14, 2018
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.
Journal: ESMO open
Published: April 20, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 19, 2017
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 07, 2016
The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 28, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
Journal: ESMO open
Published: April 21, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Journal: Breast cancer research and treatment
Published: March 03, 2016
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: March 03, 2016
Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
Journal: Asia-Pacific journal of clinical oncology
Published: December 03, 2015
Last Updated: 09/26/2026